Gilead Sciences To Present EVOKE-01 Study Results In Metastatic NSCLC At An Oral Session At ASCO 2024
Portfolio Pulse from Benzinga Newsdesk
Gilead Sciences announced that the Phase 3 EVOKE-01 study results for metastatic NSCLC will be presented at ASCO 2024. The study did not meet its primary endpoint of overall survival.
May 31, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Gilead Sciences will present the Phase 3 EVOKE-01 study results for metastatic NSCLC at ASCO 2024. The study did not meet its primary endpoint of overall survival, which could negatively impact investor sentiment.
The failure to meet the primary endpoint of overall survival in the Phase 3 EVOKE-01 study for metastatic NSCLC is likely to negatively impact investor sentiment and could lead to a short-term decline in Gilead Sciences' stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100